-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Contineum Therapeutics, Lowers Price Target to $31

Benzinga·11/07/2024 16:52:17
Listen to the news
RBC Capital analyst Brian Abrahams maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and lowers the price target from $32 to $31.